SLC29A1 and neoplasm: Targeting ENT1 may enhance T cell-mediated tumor cell killing by (i) limiting the release of adenosine by tumor cells to prevent adenosine receptor signaling, and (ii) blocking the anti-proliferative effects resulting from adenosine uptake in immune cells.